Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

B-61Impact of Sleep Quality, Depression, Daytime Sleepiness, and Fatigue on Cognition in Multiple Sclerosis.
Gene set differential analysis of time course expression profiles via sparse estimation in functional logistic model with application to time-dependent biomarker detection.
A reliability study of colour-Doppler sonography for the diagnosis of chronic cerebrospinal venous insufficiency shows low inter-rater agreement.
Intermittent alien hand syndrome and callosal apraxia in multiple sclerosis: implications for interhemispheric communication.
Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.
Understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models.
Massive peripheral nerve hypertrophy in a patient with chronic inflammatory demyelinating polyradiculoneuropathy.
Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy.
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
VIP and PACAP: Neuropeptide modulators of CNS inflammation, injury, and repair.
Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients.
Neurodegenerative diseases in the era of targeted therapeutics: how to handle a tangled issue.
Sexual problems among women with multiple sclerosis.
Risk of fractures in patients with multiple sclerosis: A population-based cohort study.
CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions.
BAFF maintains T-cell survival by inducing OPN expression in B cells.
Longitudinal associations between brain structural changes and fatigue in early MS.
Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis.
Is customized vestibular rehabilitation effective in patients with multiple sclerosis? A randomized controlled trial.
Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange.
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials.
Adrenomedullin protects from experimental autoimmune encephalomyelitis at multiple levels.
Prospective study on retinal nerve fibre layer thickness changes in isolated unilateral retrobulbar optic neuritis.
Promoting Remyelination in Multiple Sclerosis-Recent Advances.

Pages